

The FDA has issued an Emergency Use Authorization (EUA) for Casirivimab/Imdevimab for treatment of mild to moderate COVID-19.

- Inclusion criteria:
 - Outpatient COVID positive patient (mild to moderate symptoms by the NIH criteria)
 - Symptom onset within last 10 days
 - Age ≥ 18
 - Are high-risk for progressing to severe COVID-19 and/or hospitalization
 - Patient must have oxygen saturation greater than or equal to 94% on room air OR
 - If patient is on O₂, they must not have an increased oxygen requirements OR
 - If the patient has a known baseline pulse ox of less than 94% and does not meet the criteria for home oxygen, the provider must document that in his/her note for the patient to be eligible.

High risk is defined as patients who meet at least one of the following criteria:

- Obesity or being overweight (for example BMI > 25)
- Diabetes
- Immunosuppressive disease or are on immunosuppressive medication
- Chronic obstructive pulmonary disease/ other chronic respiratory disease
- Other medical conditions
- Pregnancy
- Chronic kidney disease
- Neurodevelopmental disorders
- Medical-related technological dependence
- Sickle cell disease
- Are ≥ 65 years of age
- Cardiovascular disease OR hypertension

See CDC website <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>

- Exclusion Criteria:
 - Do NOT meet inclusion criteria
 - Weight < 88 lbs
 - Require oxygen due to COVID-19 or who require an increase in oxygen from baseline
 - History of allergic reaction to monoclonal antibody administration
- **A referral and therapy plan are both required.** For more information on making a referral, call (205) 921-6305. Press “8” after recording begins.
- The patient will be observed for one hour after treatment. No visitors will be allowed in the facility.
- **Location:** 1256 Military Street South, Hamilton, AL

www.nmhs.net/covid-physician
See this link for updates, tip sheets, referral forms and more.

